肝癌的靶向治疗

Targeted therapy for hepatocellular carcinoma

肝癌是全世界第5大常见恶性肿瘤，高居男性和女性癌症死因的第2位和第6位。肝癌起病隐匿，绝大多数就诊时已属中晚期．缺乏有效的根治性治疗手段。自2007年索拉非尼被批准用于晚期肝癌一线治疗以来．靶向治疗药物为进展期肝癌患者带来新的希望。然而，近10年里肝癌的靶向治疗药物研究近乎停滞不前。随着瑞戈非尼、乐伐替尼和免疫治疗药物的相继问世。肝癌靶向治疗再次迎来曙光。

Hepatocellular carcinoma （ HCC ） is the world＇s fifth common malignant tumor, ranks as the second and sixth leading causes of cancer death in male and female. In a majority of the cases, HCC is diagnosed in advanced stage of disease when curative treatment options are not applicable. In 2007, sorafenib was approved for the first-line treatment of advanced HCC. Targeted therapy, which could improve the over- all survival and qualities of life, brought a new hope for patients with advanced HCC. Unfortunately, in the past 10 years, various drugs tested in numerous different trials failed to demonstrate any benefit. Recent studies have demonstrated the efficacy of two molecular targeted agents, the second-line agent regorafenib and the first-line agent lenvatinib. Furthermore, preliminary results of immune checkpoint inhibitors such as anti-PD-1/PD-L1 or CTLA-4 antibodies were quite encouraging. These new drugs brought dawn of targeted therapy of HCC.